Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

Elena Dozio, Valentina Corradi, Marta Proglio, Elena Vianello, Lorenzo Menicanti, Roberta Rigolini, Carlotta Caprara, Massimo de Cal, Massimiliano M. Corsi Romanelli, Claudio Ronco

Research output: Contribution to journalReview article

Abstract

In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalDiabetes Research and Clinical Practice
Volume140
DOIs
Publication statusPublished - Jun 1 2018

Keywords

  • Cardiovascular risk
  • Diabetes
  • Dialysis
  • Glycated albumin
  • Glycation
  • Hemodialysis
  • Mortality
  • Peritoneal dialysis

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)'. Together they form a unique fingerprint.

Cite this